AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01364480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of NeuroPort Arrays in the motor cortex
Description: Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
Study NCT01693250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fitbit Ultra
Description: Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
Study NCT01693250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
Study NCT02113774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial treatment according to in-vitro susceptibility
Study NCT02603679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Any brand of paclitaxel may be used, excluding nab-paclitaxel
Study NCT02603679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Palbociclib
Description: Any brand of tamoxifen may be used
Study NCT02603679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor + Palbociclib
Description: Any brand of letrozole, anastrozole or exemestane may be used
Study NCT02603679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin + Aromatase Inhibitor + Palbociclib
Description: Any brand of letrozole, anastrozole or exemestane may be used
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum-ALM + BCG
Description: Alum precipitated autoclaved L. major
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Alum precipitated autoclaved L. major
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Alum precipitated autoclaved L. major
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum-ALM + BCG
Description: Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum-ALM + BCG
Description: Alum-ALM + BCG
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Alum-ALM + BCG
Study NCT00429715 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alum-ALM + BCG
Description: Alum-ALM + BCG
Study NCT01778075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
Description: Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Study NCT01778075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
Description: Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Study NCT06090123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
Study NCT06090123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
Study NCT06090123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
Study NCT04311112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT04311112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA Low dose
Description: ZA low dose
Study NCT04311112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA high dose
Description: ZA high dose
Study NCT04103112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated compression stocking
Description: Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling.
Study NCT03498131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg Melatonin
Description: 3 mg melatonin once each day
Study NCT03498131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Melatonin
Description: 5 mg Melatonin once each day
Study NCT04713410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Study NCT04713410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Study NCT01650831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified BreathID
Description: A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
Study NCT04062747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After standard anesthesia i-Gel was placed into the patient
Study NCT04062747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu aura i
Description: After standard anesthesia ambu aura was placed into the patient
Study NCT01596712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
Study NCT01596712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
Study NCT02656966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA.
Study NCT03599778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: XELOX + apatinib's MTD
Study NCT03599778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: XELOX + apatinib's MTD
Study NCT01234038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
Study NCT01234038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: 1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
Study NCT01234038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS EIF4E Rx
Description: (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
Study NCT01234038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
Study NCT01234038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
Study NCT00610792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
Study NCT00610792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: 30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
Study NCT03249324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive-Gain Counseling (PGC)
Description: Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
Study NCT03249324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
Study NCT04251832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
Study NCT04251832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Thiosulfate
Description: Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
Study NCT02291133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
Study NCT02291133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator Vitae®
Description: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.
Study NCT02291133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Intravenous in bolus administration of bleomycin (15 mg/m2)
Study NCT01875081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Livercellgram
Description: Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery
Study NCT02435667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises
Study NCT02435667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA bone scan
Description: A DEXA scan that provides bone density measures.
Study NCT02435667 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: DEXA bone scan
Description: A DEXA scan that provides bone density measures.
Study NCT02134106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B + Doripenem
Description: Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
Study NCT00720824 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Office routine
Description: Standard vaccine administration
Study NCT00035477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
Study NCT00035477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
Study NCT03620604 — intervention group
Intervention type: DEVICE
Intervention: Stress urinary incontinence surgery
Description: All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
Study NCT00365768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Administered orally twice daily for 21 days
Study NCT00365768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally twice daily for 21 days
Study NCT02020291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foxy-5
Study NCT03933124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
Study NCT02157168 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community health worker
Description: Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey.
Study NCT03437044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Study NCT03437044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Study NCT04616404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg of artichoke extract
Description: Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
Study NCT04616404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets with no active ingredient
Study NCT03365947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HBV
Description: sc injection
Study NCT03365947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: sc injection
Study NCT00859794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
Study NCT00859794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Testing
Description: Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
Study NCT03365947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: oral tablets
Study NCT01496170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
Study NCT00859794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional electrode implantation
Description: Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
Study NCT00859794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical brain stimulation
Description: Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
Study NCT00084552 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
Study NCT00084552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
Study NCT00812461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 6 months
Study NCT00812461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study NCT01448681 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant A
Description: Use of Myblu e-cigarette with flavor A 2.4% nicotine
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant B
Description: Use of Myblu e-cigarette with flavor B 3.6% nicotine
Study NCT01496170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, orally, once per day for 7 days
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant C
Description: Use of Myblu e-cigarette with flavor C 2.5% nicotine
Study NCT01753700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UHT treated milk
Study NCT01753700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT treated milk
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant D
Description: Use of Myblu e-cigarette with flavor D 4.0% nicotine
Study NCT04430634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu variant E
Description: Use of Myblu e-cigarette with flavor E 3.6% nicotine